Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Leap Therapeutics stock | $2.9

Learn how to easily invest in Leap Therapeutics stock.

Leap Therapeutics Inc is a biotechnology business based in the US. Leap Therapeutics shares (LPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Leap Therapeutics employs 30 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Leap Therapeutics

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LPTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Leap Therapeutics stock price (NASDAQ: LPTX)

Use our graph to track the performance of LPTX stocks over time.

Leap Therapeutics shares at a glance

Information last updated 2021-10-25.
Latest market close$2.90
52-week range$1.33 - $4.17
50-day moving average $2.93
200-day moving average $1.95
Wall St. target price$4.80
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.42

Buy Leap Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Leap Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Leap Therapeutics price performance over time

Historical closes compared with the close of $2.9 from 2021-10-25

1 week (2021-10-19) -6.15%
1 month (2021-09-27) -18.77%
3 months (2021-07-27) 114.81%
6 months (2021-04-27) 69.59%
1 year (2020-10-26) 45.00%
2 years (2019-10-25) 161.26%
3 years (2018-10-26) 5.11
5 years (2016-10-23) N/A

Is Leap Therapeutics under- or over-valued?

Valuing Leap Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Leap Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Leap Therapeutics's PEG ratio

Leap Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Leap Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Leap Therapeutics financials

Revenue TTM $1.5 million
Gross profit TTM $1.5 million
Return on assets TTM -39.09%
Return on equity TTM -72.37%
Profit margin 0%
Book value $0.50
Market capitalisation $254 million

TTM: trailing 12 months

Shorting Leap Therapeutics shares

There are currently 11.4 million Leap Therapeutics shares held short by investors – that's known as Leap Therapeutics's "short interest". This figure is 152.3% up from 4.5 million last month.

There are a few different ways that this level of interest in shorting Leap Therapeutics shares can be evaluated.

Leap Therapeutics's "short interest ratio" (SIR)

Leap Therapeutics's "short interest ratio" (SIR) is the quantity of Leap Therapeutics shares currently shorted divided by the average quantity of Leap Therapeutics shares traded daily (recently around 13.7 million). Leap Therapeutics's SIR currently stands at 0.83. In other words for every 100,000 Leap Therapeutics shares traded daily on the market, roughly 830 shares are currently held short.

However Leap Therapeutics's short interest can also be evaluated against the total number of Leap Therapeutics shares, or, against the total number of tradable Leap Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Leap Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Leap Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1833% of the tradable shares (for every 100,000 tradable Leap Therapeutics shares, roughly 183 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Leap Therapeutics.

Find out more about how you can short Leap Therapeutics stock.

Leap Therapeutics share dividends

We're not expecting Leap Therapeutics to pay a dividend over the next 12 months.

Leap Therapeutics share price volatility

Over the last 12 months, Leap Therapeutics's shares have ranged in value from as little as $1.33 up to $4.17. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Leap Therapeutics's is 0.4842. This would suggest that Leap Therapeutics's shares are less volatile than average (for this exchange).

Leap Therapeutics overview

Leap Therapeutics, Inc. , a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc.

Frequently asked questions

What percentage of Leap Therapeutics is owned by insiders or institutions?
Currently 11.538% of Leap Therapeutics shares are held by insiders and 33.329% by institutions.
How many people work for Leap Therapeutics?
Latest data suggests 30 work at Leap Therapeutics.
When does the fiscal year end for Leap Therapeutics?
Leap Therapeutics's fiscal year ends in December.
Where is Leap Therapeutics based?
Leap Therapeutics's address is: 47 Thorndike Street, Cambridge, MA, United States, 02141
What is Leap Therapeutics's ISIN number?
Leap Therapeutics's international securities identification number is: US52187K1016
What is Leap Therapeutics's CUSIP number?
Leap Therapeutics's Committee on Uniform Securities Identification Procedures number is: 52187K101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site